Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2016-08-23 Share Issue/Capital Cha…
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 1% confidence The document title is "Publication du nombre d'actions composant le capital social et du nombre total de droits de vote" (Publication of the number of shares comprising the share capital and the total number of voting rights). It explicitly references French regulatory articles (Code de commerce and AMF General Regulation) and provides a table detailing the number of shares and voting rights as of a specific date (31/07/2016). This content directly relates to changes in the company's capital structure and ownership notification thresholds, which falls under Share Issue/Capital Change (SHA) or Major Shareholding Notification (MRQ). Since it is a formal publication detailing the total number of shares and voting rights, it is most accurately classified as a notification regarding the capital structure, fitting the definition of 'Share Issue/Capital Change' (SHA), although it is a periodic update rather than a new issue. Given the options, SHA is the best fit for reporting the total share count and voting rights, which underpins capital structure reporting. It is not a general earnings release (ER) or a full annual report (10-K).
2016-08-23 French
Rachat d'actions / Contrat de liquidité Information relative au contrat de liquidité
Capital/Financing Update Classification · 1% confidence The document is titled "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ AU 30 Juin 2016" (Half-yearly balance sheet of the liquidity contract as of June 30, 2016). This document details the status of a liquidity contract (market making agreement) at a specific semi-annual point in time (June 30, 2016). This type of filing, which reports on specific financial arrangements or operational metrics outside of standard periodic financial reports (like 10-K or IR), often falls under general regulatory announcements or specific financial updates. Since it is a report on a specific financial arrangement (liquidity contract balance) and not a comprehensive quarterly report (IR), earnings release (ER), or a general regulatory filing (RNS), it best fits the category for specific financial/operational updates. Given the options, it is a specific financial disclosure related to market operations. It is not a standard 10-K, IR, ER, or a management/board change. It is a specific financial disclosure. Since there isn't a perfect fit for 'Liquidity Contract Update', I must evaluate the closest options. It is a periodic report (semestriel/half-yearly) but not a comprehensive financial report (IR). It is a specific financial disclosure. Given the available codes, 'IR' (Interim/Quarterly Report) is for comprehensive reports. 'RNS' (Regulatory Filings) is a fallback. 'CAP' (Capital/Financing Update) is related to capital structure changes, which liquidity contracts indirectly support. However, the content is a specific periodic report on a financial service agreement. In many jurisdictions, these specific periodic operational/financial updates that aren't full financial statements default to a general regulatory filing category. Given the specific nature and the lack of a dedicated code, 'RNS' (Regulatory Filings) is the most appropriate fallback for a specific, non-standard periodic disclosure.
2016-07-06 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document provides information regarding the total number of shares and voting rights ('nombre total de droits de vote et d'actions') as required by French commercial code (Article L. 233-8 II) and AMF regulations (Article 223-16). This type of mandatory disclosure, detailing share structure and voting power, is a specific regulatory filing. It is not an Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). Since it deals specifically with share structure and voting rights disclosure, it fits best under the general 'Regulatory Filings' (RNS) category as there is no specific code for 'Share Structure Disclosure' among the provided options, although it is related to share capital changes. Given the context of mandatory regulatory reporting on voting rights, RNS is the most appropriate fallback, although it is a very specific type of regulatory filing.
2016-07-06 French
Share buybacks / Liquidity contracts Information related to liquidity contracts
Capital/Financing Update Classification · 1% confidence The document is titled "HALF-YEAR REPORT ON THE LIQUIDITY CONTRACT AT 30 JUNE 2016" and provides specific figures related to a liquidity contract (share count and cash balance) as of a mid-year date (June 30, 2016). This content is highly specific, focusing on a financial instrument/contract rather than comprehensive financial statements (10-K or IR) or a general earnings announcement (ER). It details the status of a specific financial arrangement, which aligns best with specialized financial updates. Given the options, this is a specific financial disclosure. It is not a general Earnings Release (ER), nor a full Interim Report (IR), but rather a report on a specific financial mechanism (liquidity contract). Since there is no specific code for 'Liquidity Contract Report', I must evaluate the closest fit. It is a periodic financial disclosure. It is too specific for a general Regulatory Filing (RNS). It is not a dividend notice (DIV), capital change (CAP/SHA), or management change (MANG). It is a report on a financial contract, which often falls under specialized financial disclosures. Given the context of 'Half-Year Report' combined with specific financial contract details, it most closely resembles a specialized financial update. However, none of the codes perfectly match 'Liquidity Contract Report'. Since it is a report detailing financial status for a period shorter than a year, 'Interim / Quarterly Report' (IR) is the closest general category for periodic financial reporting, although this document is highly focused. Alternatively, if this is considered a mandatory disclosure related to market operations, 'Regulatory Filings' (RNS) might apply. Given the explicit mention of 'HALF-YEAR REPORT', IR is a strong candidate, but the content is extremely narrow. Since it is a report detailing financial status for a specific period (half-year), and not just an announcement of a report, I will classify it as Interim Report (IR), as it is a periodic financial disclosure.
2016-07-06 English
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Legal Proceedings Report Classification · 1% confidence The document is a press release dated June 17, 2016, announcing the results of a futility analysis for the ABX203 clinical trial in chronic hepatitis B. It details clinical trial progress (ABX203 and ABX464), pipeline updates, and concludes by announcing that senior management will host a conference call to discuss these developments, providing dial-in details. This structure—announcing material operational/clinical news and immediately scheduling a call to discuss it—is characteristic of an Earnings Release (ER) or a general operational update that often accompanies earnings, but since it focuses purely on clinical trial results and pipeline progress rather than comprehensive financial performance for a period, it fits best as a significant operational update. However, the key feature is the announcement of clinical trial results and the immediate scheduling of a conference call for discussion. This strongly suggests an Earnings Release (ER) or a related operational update. Given the focus on trial outcomes and pipeline, and the explicit mention of a conference call to discuss 'these developments,' ER is the most appropriate fit among the options, as these announcements often precede or substitute for a formal quarterly report summary.
2016-06-17 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Earnings Release Classification · 1% confidence The document is a press release dated June 17, 2016, announcing an interim analysis of a Phase IIb/III clinical trial (ABX203 for Hepatitis B) which indicated the primary endpoint was unlikely to be met. It also provides updates on other pipeline candidates (ABX464 for HIV) and mentions an upcoming R&D Day and a conference call to discuss these developments. This content structure—announcing key clinical trial updates, pipeline progress, and scheduling an investor call—is characteristic of an Earnings Release (ER) or a general press release detailing operational and financial milestones. Since it focuses on key results and updates rather than being a full, comprehensive periodic report (like 10-K or IR), 'ER' (Earnings Release) is the most appropriate classification, as these releases often contain operational updates alongside financial highlights, even if specific quarterly figures aren't the main focus. It is not a transcript (CT), a formal annual report (10-K), or a proxy statement (DEF 14A). The inclusion of conference call details strongly supports the ER classification. FY 2016
2016-06-17 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.